62 results about "Ophthalmic solutions" patented technology

Disclosed are ophthalmic solutions such as packaging solutions for storing ophthalmic devices and lens care solutions for cleaning, disinfecting, rinsing and/or storing ophthalmic devices. The ophthalmic solutions contain at least a polymerization product obtained from a monomeric mixture comprising (a) a monomer bearing a center of permanent positive charge and (b) a non-ionic ethylenically unsaturated monomer, wherein the solution has an osmolality of at least about 200 mOsm/kg, and a pH of about 4 to about 9.

The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided. Also provided are implants containing a drug core emplacable in a punctum adjacent to an eye of a patient for controlled release of a therapeutic agent such as latanoprost for the treatment of glaucoma, the drug core containing a polymer such as cross-linked silicone, a therapeutic agent, and an excipient, wherein the excipient can increase the rate of release of the agent from the drug core, or can increase the drug loading in the core without loss of desirable homogeneity of the agent within the core, or can improve retention of the agent in the eye or in tear fluid, or can increase corneal penetration of the agent into the eye.

The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.

The present invention provides stable ophthalmic solutions comprising a compound with serotonergic 5-HT₂ receptor activity and at least one stabilizer, together with methods of using such solutions to treat glaucoma and to lower intraocular pressure.

A device for dispensing ophthalmic solutions to a user's eyes comprising a container for holding ophthalmic solutions, transfer tubing attached to the container for dispensing and applying said solution and a clip attached to the container for attaching said applicator to eyeglasses. The transfer tubing is the clip by being formed into the shape of a clip for attaching said eye solution applicator to eyeglasses.

A dispensing tip apparatus for an eye drop dispenser to administer topical ophthalmic solutions is described. The apparatus integrates an ophthalmic solution-dispensing tip with an optical gauging assembly. The tip provides continuous visual feedback about it orientation and relationship to the eye. The dispensing tip when attached to any standard topical ophthalmic solution dispensing bottle or reservoir enables the user to view a target, visually align the dispenser tip, and administer an eye drop with precision. There is also a visual feedback by which the dispenser tip is prevented from gaining too close proximity and contacting the eye, thus preventing contamination of the medication and its dispenser. The visual feedback can also contain textual or graphic information that serves as a promotional advertisement.

Disclosed herein are ophthalmic solutions and methods of using the solutions which comprise a complex of at least one cationic component and an anionic polymer, wherein the complex can be used as an antimicrobial agent. The solutions described have complexes which can be dissolved in aqueous ophthalmic solutions due to both lower charge load and lower total polymer concentrations than commonly taught. The complexes display different antimicrobial profiles than the non-complexed antimicrobial agents.

The present invention relates to mucomimetic and ophthalmic solutions comprising a cationic multimeric antimicrobial agent such as polyaminopropyl biguanide and a magnesium, calcium or magnesium/calcium complex of an anionic polymer such as hyaluronate, alginate, carboxymethyl cellulose, chondroitin sulfate or mixtures thereof. In specific embodiments, the solutions include additional components such as a surfactant, preferably polysorbate 20, a viscosity-modifying agent, preferably hydroxypropylmethyl cellulose, carboxymethyl cellulose or hydroxyethyl cellulose, a tonicity agent and a buffer. The solutions are biocompatible with and are highly comfortable when administered to mucous membranes, including those of the eye, as well as are effective disinfectants.

The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.

The invention relates to an aqueous ophthalmic solution comprising 0.00001 to about 10.0 percent by weight L-histidine, 0.0001 to 3.0 percent by weight hydrogen peroxide, and optionally 0.1 to 500 parts per million of a preservative that provides superior preservative efficacy especially as against fungal microbes. These solutions may be employed in various ways including cleaning contact lenses, rinsing lenses while in the eye, storing lenses and in delivering active pharmaceutical agents to the eye.

The invention relates to an aqueous ophthalmic solution comprising 0.01 to about 1.0 percent by weight L-histidine; 0.01 to 0.0001 percent by weight hydrogen peroxide; 0.1 to 500 parts per million of a cationic polymeric preservative that provides superior preservative efficacy especially as against fungal microbes. These solutions may be employed in various ways including cleaning contact lenses, rinsing lenses while in the eye, storing lenses and in delivering active pharmaceutical agents to the eye.

This invention generally relates to an ophthalmic solution comprising cannabinoids for the treatment of glaucoma. Also disclosed is an ophthalmic solution comprising cannabinoids for symptomatic relief of conjunctival inflammation. Cannabinoids are selected to achieve the specific purpose of the respective ophthalmic solution.

The present disclosure is directed to an injector device for delivering an ophthalmic solution to a cornea of an eye. The device may include a base configured to contact part of the eye, and a needle connected to the base, wherein needle may deliver the ophthalmic solution to the cornea.

A Chinese medicine in the form of eyedrops for treating ophthalmopathy, such as cataract, presbyopia, muscae volitantes, xerophthalmia, etc, is prepared from 10 Chinese-medicinal materials including coptis root, ledebouriella root, ash bark, alum, etc through sequentially decocting, filtering, distilling, cooling and sterilizing.

The methods and compositions of the present invention generally relate to ophthalmic solutions. Specifically, the methods and compositions relate to at least the following: ophthalmic solutions that are usable as eye drops for contact lens wearers, eye rinsing solutions, and ophthalmic solutions that are usable as contact lens wetting agents. In a wetting solution aspect, the present invention provides a contact lens wetting solution that includes: a cesium salt, a rubidium salt or a combination thereof; and, water, wherein the wetting solution has a viscosity of 1 to 3 cps.

The present invention relates to ophthalmic compositions comprising a pH between about 6 and about 8 and about 50 to about 1000 ppm hydrogen peroxide and at least one phosphate buffer. The ophthalmic compositions of the present invention display improved antifungal efficacy against fungi, including candidas albicans and fusarium solani.

The present invention relates to stabilized ophthalmic solutions comprising at least one peroxide. In one embodiment, the present invention relates to an ophthalmic solution comprising a pH between about 6 and about 8 and about 50 to about 1000 ppm hydrogen peroxide and about 0.005 wt % (50 ppm) to about 0.05 wt % (500 ppm) at least one salt of diethylenetriamine pentaacetic acid selected from the group consisting of calcium salts of diethylenetriamine pentaacetic acid, zinc salts of diethylenetriamine pentaacetic acid and mixed calcium/zinc salts of diethylenetriamine pentaacetic acid.

The present invention further relates to a method for preserving ophthalmic solution comprising at least one peroxide.

An ophthalmic solution discharging apparatus is described. The ophthalmic solution discharging apparatus comprises: a base portion comprising a cylindrical base for receiving and removably engaging a dropper of an ophthalmic solution container; a head portion comprising a micro nozzle portion through which ophthalmic solution is discharged, a shield portion that cylindrically surrounds the micro nozzle portion, the shield portion comprising a wall containing an opening for viewing a portion of the micro nozzle portion during discharge; a neck portion that connects the base portion and the head portion; and an internal cavity portion defined by the base, head and neck portions and comprising a (1) container engagement portion for receiving and removably engaging the ophthalmic solution container, and (2) a funnel portion for transporting and discharging ophthalmic solution through the micro nozzle portion at a lesser volume than would otherwise be discharged by the dropper of the ophthalmic solution container.

Provided is an ophthalmic solution of which preservative component, hexamethylene biguanide, contained therein is inhibited from being adsorbed on soft contact lenses and eye droppers. The ophthalmic solution contains, at a specific ratio, (A) hydroxypropyl methylcellulose having 28.0 to 30.0 mass % methoxy groups and 7.0 to 12.0 mass % hydroxypropoxy groups, both with respect to the total amount of the hydroxypropyl methylcellulose, at a methoxy group/hydroxypropoxy group ratio of 2.5 to 4.0 by mass, wherein a 2 mass % aqueous solution of the hydroxypropyl methylcellulose at 20° C. has a viscosity of 50 to 4000 mPa·s; (B) sodium chloride or potassium chloride; (C) hexamethylene biguanide or a salt thereof; (D) 2-methacryloyloxyethyl phosphorylcholine/butyl methacrylate copolymer; and (E) water.